已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

医学 临床试验 分级(工程) 重症监护医学 医学物理学 内科学 工程类 土木工程
作者
Nathan I. Cherny,Richard Sullivan,Urania Dafni,J. Martijn Kerst,Alberto Sobrero,Christoph Zielinski,Elisabeth G.E. de Vries,Martine Piccart
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:26 (8): 1547-1573 被引量:706
标识
DOI:10.1093/annonc/mdv249
摘要

ABSTRACT

The value of any new therapeutic strategy or treatment is determined by the magnitude of its clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment options is derived from clinical research, in particular phase III randomised trials, which generate unbiased data regarding the efficacy, benefit and safety of new therapeutic approaches. To date, there is no standard tool for grading the magnitude of clinical benefit of cancer therapies, which may range from trivial (median progression-free survival advantage of only a few weeks) to substantial (improved long-term survival). Indeed, in the absence of a standardised approach for grading the magnitude of clinical benefit, conclusions and recommendations derived from studies are often hotly disputed and very modest incremental advances have often been presented, discussed and promoted as major advances or ‘breakthroughs'. Recognising the importance of presenting clear and unbiased statements regarding the magnitude of the clinical benefit from new therapeutic approaches derived from high-quality clinical trials, the European Society for Medical Oncology (ESMO) has developed a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). This tool uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from a new anti-cancer treatment. The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care. The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雪莉完成签到 ,获得积分10
1秒前
1秒前
1秒前
小蘑菇的应助被潇洒的代双采纳,获得10
1秒前
鹅鹅发布了新的文献求助10
1秒前
1秒前
yuri发布了新的文献求助10
2秒前
3秒前
林子完成签到,获得积分10
3秒前
lizrt完成签到 ,获得积分10
3秒前
LuXiaoyu的应助被玄牝采纳,获得10
4秒前
5秒前
斯文明杰发布了新的文献求助10
5秒前
drizzle发布了新的文献求助10
7秒前
林子发布了新的文献求助10
7秒前
7秒前
xxxxyyy完成签到,获得积分10
8秒前
8秒前
LuXiaoyu的应助被含蓄大雁采纳,获得10
10秒前
12秒前
13秒前
丘比特的应助被whz采纳,获得10
14秒前
Crssss的应助被零可林采纳,获得30
15秒前
xinyuanjia的应助被hfhkjh采纳,获得10
15秒前
zqh完成签到,获得积分10
16秒前
Pan完成签到,获得积分10
17秒前
菜菜的树发布了新的文献求助10
18秒前
yuan完成签到 ,获得积分10
18秒前
18秒前
18秒前
20秒前
酷波er的应助被20250702采纳,获得10
20秒前
斯文明杰完成签到,获得积分10
22秒前
orixero的应助被wonderfulwisdom采纳,获得10
22秒前
刘梦宇完成签到 ,获得积分10
22秒前
sinba发布了新的文献求助20
22秒前
WangZD发布了新的文献求助10
26秒前
科研通AI2S的应助被科研通管家采纳,获得10
26秒前
搜集达人的应助被科研通管家采纳,获得10
26秒前
852的应助被科研通管家采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179198
求助须知:如何正确求助?哪些是违规求助? 9569781
关于积分的说明 21806509
捐赠科研通 7774542
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556929
邀请新用户注册赠送积分活动 2478652